Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Binkui LiOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05810350 | Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles | unknown | Phase 2 | 40 | Three Gorges Hospital of Chongqing UniversityOTHER | 1 | Apr 13, 2023 |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05556200 | A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs | unknown | Phase 2 | 58 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05809869 | Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma | unknown | Phase 2 | 25 | The University of Hong KongOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04389177 | Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05641493 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation | unknown | Phase 1 / Phase 2 | 49 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05803915 | Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy | unknown | Phase 2 | 57 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03769285 | Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial(SPRINTR-Pilot) | unknown | Phase 2 | 120 | Women's College HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05746728 | Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer | unknown | Phase 1 / Phase 2 | 45 | Huihua XiongOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05801107 | Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 2 | 30 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT02285530 | GDF15 Based TPF Induction Chemotherapy for OSCC Patients | unknown | Phase 2 | 72 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04840004 | Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer | unknown | Phase 2 | 24 | PlusVitech S.L.OTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04667793 | Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05798455 | Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Tabriz University of Medical SciencesOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05790200 | Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05791136 | Immunotherapy After Radiotherapy in Elderly ESCC(TREE) | unknown | Phase 2 | 30 | The Central Hospital of Lishui CityOTHER | 0 | Mar 30, 2023 | clinicaltrials |
| NCT00492778 | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | unknown | Phase 2 | 165 | GOG FoundationNETWORK | 2 | Mar 29, 2023 | clinicaltrials |
| NCT03280667 | Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma(KEYPAD) | unknown | Phase 2 | 59 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04368078 | Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 76 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04443309 | Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04646837 | Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models | unknown | Phase 1 / Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04974866 | Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma | unknown | Phase 2 | 20 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04974879 | Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer | unknown | Phase 2 | 20 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05048017 | Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03975114 | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)(MILES-5) | unknown | Phase 2 | 460 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04396457 | Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 | unknown | Phase 2 | 50 | National Hospital Organization Nagoya Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05097209 | Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 200 | Wei JiangOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05541146 | Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04663035 | Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC | unknown | Phase 2 | 120 | Ming ZhaoOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT04992715 | PD-L1 Expression in Lung Cancer(PELICAN) | unknown | Phase 2 | 15 | NanoMab Technology (UK) LimitedINDUSTRY | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05407519 | A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | unknown | Phase 2 | 40 | Anhui Provincial HospitalOTHER_GOV | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05616390 | Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05777707 | Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma | unknown | Phase 1 / Phase 2 | 89 | Beijing Friendship HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05775874 | A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | unknown | Phase 2 | 80 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT05323890 | Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma. | unknown | Phase 2 | 15 | Shandong Cancer Hospital and InstituteOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05408221 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 576 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05761132 | Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study(Apollo) | unknown | Phase 2 | 40 | Leiden University Medical CenterOTHER | 0 | Mar 9, 2023 | clinicaltrials |
| NCT01590355 | A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)(ORATOR) | unknown | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Mar 8, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05760430 | The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma | unknown | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05760599 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | unknown | Phase 2 | 30 | Shi MingOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04338620 | Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC | unknown | Phase 2 | 94 | Tang-Du HospitalOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05163483 | Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer | unknown | Phase 2 | 87 | Ruihua XuOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05754736 | Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations. | unknown | Phase 2 | 50 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT03787602 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | unknown | Phase 1 / Phase 2 | 115 | Kartos Therapeutics, Inc.INDUSTRY | 10 | Mar 2, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 13, 2023source: clinicaltrials